---
freshness:
  last-reviewed: 2025-01-28
  data-year: 2025
  review-cycle: 6
  sections:
    - name: "Phase 1: Immediate Actions"
      data-year: 2025
    - name: "Phase 2: Expansion"
      data-year: 2025
    - name: "Phase 3: Comprehensive Framework"
      data-year: 2025
    - name: "Phase 4: Full Integration"
      data-year: 2025
notes:
  - Update after congressional session to reflect any harm reduction legislation movement.
  - Revisit SCS authorization status after OnPoint NYC evaluation milestones.
  - Monitor DEA methadone rulemaking progress.
  - Flag opioid settlement fund allocation decisions for harm reduction.
sources:
  count: 18
  verified: 2025-01-28
  broken: 0
---

# Harm Reduction: Implementation Roadmap

## Overview

This roadmap outlines a phased strategy for implementing comprehensive harm reduction in the United States. It acknowledges political realities, sequences interventions by feasibility, and builds toward a long-term vision. The approach prioritizes saving lives immediately while building infrastructure for systemic change.

---

## Strategic Principles

| Principle | Application |
|-----------|-------------|
| Save lives first | Prioritize naloxone and SSP expansion -- interventions with immediate mortality impact |
| Build on success | Expand proven programs before launching new ones; use data to build political support |
| Create bipartisan pathways | Frame harm reduction in terms that resonate across political spectrum: fiscal savings, public safety, family survival |
| Center equity | Ensure expansions reach communities with highest need and greatest disparities |
| Sequence politically | Start with least controversial interventions; build momentum for harder fights |
| Evaluate rigorously | Mandate independent evaluation; use data to counter opposition and improve programs |

---

## Phase 1: Immediate Actions (0-12 Months)

### Priority: Maximize Impact with Existing Authority

These actions can be taken without major new legislation, using existing authority, executive action, and current funding streams.

| Action | Authority | Lead Agency | Cost |
|--------|-----------|-------------|------|
| Expand naloxone distribution through existing grant programs | Administrative | SAMHSA/CDC | $50M reallocation |
| Issue federal guidance affirming FTS legality | Administrative | DOJ/HHS | Minimal |
| Permanent telehealth MAT prescribing rule | DEA rulemaking | DEA | Minimal |
| Expand methadone take-home flexibility (permanent) | DEA/SAMHSA rulemaking | DEA/SAMHSA | Minimal |
| Declare public health emergency for overdose crisis | Presidential | White House | Unlocks authorities |
| Direct opioid settlement guidance toward harm reduction | HHS guidance | HHS | No federal cost |
| Expand SAMHSA Harm Reduction Grant Program | Appropriations | SAMHSA | $50M increase |
| Launch federal anti-stigma campaign | Administrative | HHS/ONDCP | $25M |

### Phase 1 Metrics

| Metric | Baseline (2024) | Target (End of Phase 1) |
|--------|-----------------|------------------------|
| Naloxone kits distributed (annual) | ~5 million | 7 million |
| States with legal FTS | 30 + D.C. | 40 + D.C. |
| MAT providers actively prescribing buprenorphine | ~65,000 | 80,000 |
| Methadone take-home doses authorized (multi-day) | COVID-era flexibility | Permanent rule |
| SAMHSA harm reduction grants | $30 million | $80 million |

### Phase 1 Risks

| Risk | Likelihood | Mitigation |
|------|-----------|------------|
| Political backlash to executive actions | Medium | Frame as bipartisan emergency response; emphasize fiscal savings |
| DEA resistance to methadone reform | Medium-High | Congressional pressure; HHS leadership engagement |
| Opioid settlement fund diversion | High | Model state legislation earmarking settlement funds; public transparency requirements |
| Inadequate appropriations increase | Medium | Build bipartisan coalition; leverage crisis data |

---

## Phase 2: Expansion (12-24 Months)

### Priority: Legislative Foundation and Program Scale-Up

Phase 2 requires Congressional action on targeted legislation and significant funding increases.

| Action | Vehicle | Lead | Cost |
|--------|---------|------|------|
| Pass Harm Reduction Access Act (see [11-legislation.md](11-legislation.md)) | Federal legislation | Congress | $400M/year |
| Remove federal ban on syringe purchase with federal funds | Appropriations / standalone bill | Congress | $25M/year |
| Legalize FTS and drug checking nationally | Federal legislation | Congress | $10M/year |
| Fund 100 new SSPs in underserved areas | SAMHSA grants | SAMHSA | $50M/year |
| Fund 200 mobile harm reduction units | New grant program | SAMHSA | $40M/year |
| Mandate ED-initiated MAT in Medicare/Medicaid | CMS regulation | CMS | $75M/year |
| Fund 25-city FTIR drug checking pilot | New grant program | CDC/SAMHSA | $15M/year |
| Establish Good Samaritan law minimum standards | Federal legislation | Congress | Minimal |

### Phase 2 Metrics

| Metric | Baseline (End of Phase 1) | Target (End of Phase 2) |
|--------|--------------------------|------------------------|
| SSPs operating | ~530 | 630 |
| Rural SSP coverage | 12% of rural communities | 25% of rural communities |
| Naloxone kits distributed (annual) | 7 million | 10 million |
| Overdose deaths (annual) | ~105,000 | <95,000 |
| Treatment gap (need MAT, do not receive) | 2.3 million | 1.8 million |
| States with drug checking legal | 40 + D.C. | 48 + D.C. |
| EDs offering MAT initiation | ~35% | 60% |

### Phase 2 Risks

| Risk | Likelihood | Mitigation |
|------|-----------|------------|
| Harm Reduction Access Act fails to pass | Medium | Build bipartisan support; start with committee hearings and evidence presentations |
| Syringe purchase ban maintained by riders | High | Separate legislation; amendment strategy; public campaign |
| Community opposition to new SSPs | Medium | Good Neighbor Agreements; community engagement protocols; evidence sharing |
| Provider resistance to MAT mandate | Medium | Education; technical assistance; peer champion programs |

---

## Phase 3: Comprehensive Framework (24-48 Months)

### Priority: Supervised Consumption and Systemic Integration

Phase 3 tackles the most politically challenging interventions while integrating harm reduction into mainstream healthcare.

| Action | Vehicle | Lead | Cost |
|--------|---------|------|------|
| Pass Supervised Consumption Authorization Act (see [11-legislation.md](11-legislation.md)) | Federal legislation | Congress | $50M/year (10 pilot sites) |
| Authorize pharmacy-based methadone dispensing | DEA rulemaking + Congressional action | DEA/Congress | $30M/year (transition costs) |
| Require MAT in all federal prisons | BOP directive + legislation | BOP/Congress | $50M/year |
| Require MAT in all state prisons/jails (as condition of DOJ funding) | Federal legislation | Congress/DOJ | $200M/year (grants to states) |
| Integrate harm reduction into Medicaid managed care standards | CMS regulation | CMS | State-shared cost |
| Establish national drug supply monitoring network | CDC infrastructure | CDC | $25M/year |
| Fund national harm reduction training center | SAMHSA grant | SAMHSA | $10M/year |

### Phase 3 Metrics

| Metric | Baseline (End of Phase 2) | Target (End of Phase 3) |
|--------|--------------------------|------------------------|
| Supervised consumption sites operating | 2 (NYC) | 12 (10 pilot + NYC) |
| Overdose deaths at SCS | 0 | 0 |
| Pharmacy methadone dispensing | 0 states | 10+ states |
| Federal prisons offering MAT | Partial | 100% |
| State correctional facilities offering MAT | ~30% | 60% |
| Overdose deaths (annual) | <95,000 | <80,000 |
| SSPs operating | 630 | 750 |
| Treatment gap | 1.8 million | 1.2 million |

### Phase 3 Risks

| Risk | Likelihood | Mitigation |
|------|-----------|------------|
| SCS legislation fails | Medium-High | Start with pilot authorization; build evidence from OnPoint NYC |
| Legal challenges to SCS | High | Clear federal statutory authority; DOJ cooperation; strong regulatory framework |
| NIMBY opposition to SCS siting | High | Community engagement protocols; Good Neighbor Agreements; equity-based siting |
| Pharmacy resistance to methadone dispensing | Medium | Phased implementation; training and technical assistance; financial incentives |
| Correctional system resistance | High | Litigation (8th Amendment); conditions on federal funding; advocacy campaigns |

---

## Phase 4: Full Integration (48-72+ Months)

### Priority: Sustainable, Equitable, Comprehensive System

Phase 4 envisions the full integration of harm reduction into American healthcare and public health systems.

| Action | Vehicle | Lead | Cost |
|--------|---------|------|------|
| Establish permanent federal harm reduction funding stream | Legislation (trust fund or mandatory spending) | Congress | $1 billion/year |
| Harm reduction in all 50 states (SSPs, naloxone, drug checking, MAT) | State legislation + federal incentives | States/Federal | Shared cost |
| SCS expanded beyond pilot phase | Federal/state legislation | States | $100M/year (25+ sites) |
| National drug checking network operational | CDC infrastructure | CDC | $50M/year |
| Harm reduction integrated into all healthcare training | Accreditation standards | Medical/nursing accreditation bodies | Minimal federal cost |
| Decriminalization of drug paraphernalia nationwide | Federal/state legislation | Congress/States | Minimal |
| Health equity targets met for all populations | HHS monitoring | HHS | Embedded in program costs |

### Phase 4 Metrics (Vision)

| Metric | Target |
|--------|--------|
| Overdose deaths (annual) | <50,000 (50%+ reduction from peak) |
| Treatment gap | <500,000 |
| HIV cases from injection drug use | <500/year |
| HCV cases from injection drug use | <10,000/year |
| SSPs operating | 1,000+ |
| SCS operating | 50+ (in states that authorize) |
| Every county has naloxone access | 100% |
| Every county has MAT access | 100% |
| Every state has SSP authorization | 50/50 |

---

## Political Sequencing Strategy

### From Least to Most Controversial

```text
Most Feasible (Start Here)
│
├── Naloxone expansion (near-universal support)
├── Good Samaritan laws (bipartisan support)
├── MAT access expansion (bipartisan support)
│
├── SSP expansion (broad support; some opposition)
├── FTS/drug checking legalization (growing support)
├── Federal syringe purchase funding (moderate opposition)
│
├── Safer smoking supplies (moderate opposition)
├── Methadone pharmacy access (institutional resistance)
├── Correctional MAT mandates (some opposition)
│
├── Supervised consumption site authorization (significant opposition)
├── Drug paraphernalia decriminalization (significant opposition)
│
Most Challenging (Build Toward)
```

### Building Blocks

Each phase creates the political foundation for the next:

1. **Naloxone success stories** build public understanding that saving lives is the priority
2. **SSP outcome data** demonstrates that harm reduction does not increase drug use
3. **MAT expansion** normalizes medication-based treatment and reduces provider stigma
4. **Drug checking results** create public awareness of the contaminated drug supply
5. **OnPoint NYC evaluation data** provides the evidence base for SCS expansion
6. **Comprehensive program outcomes** support the case for permanent funding

---

## Milestone Timeline

| Year | Key Milestones |
|------|---------------|
| Year 1 | Federal guidance on FTS; permanent telehealth MAT; expanded naloxone distribution; anti-stigma campaign launch |
| Year 2 | Harm Reduction Access Act passed; syringe purchase ban removed; 100 new SSPs funded; drug checking pilots launched |
| Year 3 | SCS pilot authorization; pharmacy methadone rulemaking; federal prison MAT mandate; Medicaid harm reduction integration |
| Year 4 | SCS pilot sites opening; national drug checking network; correctional MAT expansion |
| Year 5 | SCS evaluation data published; permanent harm reduction funding stream established |
| Year 6+ | Full integration; equity targets; paraphernalia decriminalization; sustained investment |

---

## Total Investment Framework

| Phase | Duration | Annual Federal Cost | Cumulative |
|-------|----------|--------------------|-----------|
| Phase 1 | 0-12 months | $125 million | $125 million |
| Phase 2 | 12-24 months | $615 million | $740 million |
| Phase 3 | 24-48 months | $365 million | $1.47 billion |
| Phase 4 | 48-72+ months | $1.15 billion | ~$4.9 billion (through Year 6) |

**Context**: The total six-year investment of approximately $4.9 billion represents less than 0.5% of the estimated annual economic cost of the overdose crisis ($1+ trillion). It is comparable to the total federal investment in HIV prevention since the beginning of the epidemic, adjusted for inflation.

---

## Dependencies and Critical Path

```text
Phase 1 Executive Actions
        │
        ├── Naloxone expansion ──→ Lives saved immediately
        │
        ├── FTS guidance ──→ State legalization ──→ Drug checking pilots
        │
        ├── Telehealth MAT rule ──→ Provider adoption ──→ Treatment gap reduction
        │
        └── Political foundation ──→ Phase 2 legislation
                                          │
                                          ├── Harm Reduction Access Act
                                          │         │
                                          │         └── SSP expansion
                                          │         └── Naloxone scale-up
                                          │         └── Drug checking funding
                                          │
                                          └── Phase 3 SCS authorization
                                                    │
                                                    └── Pilot sites
                                                    └── Evaluation
                                                    └── Phase 4 expansion
```

---

## Document Navigation

| Previous | Next |
|----------|------|
| [Solutions](07-solutions.md) | [Resources](09-resources.md) |

**Section Navigation:**
[Overview](01-overview.md) | [Current State](02-current-state.md) | [History](03-history.md) | [Root Causes](04-root-causes.md) | [Stakeholders](05-stakeholders.md) | [Opposition](06-opposition.md) | [Solutions](07-solutions.md) | [Roadmap](08-roadmap.md) | [Resources](09-resources.md) | [Actions](10-actions.md) | [Legislation](11-legislation.md) | [Perspectives](12-perspectives.md)
